Published in Clin Drug Investig on September 22, 2017
Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. N Engl J Med (2016) 3.90
Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Pain Med (2015) 1.10
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med (2009) 1.04
Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Curr Med Res Opin (2013) 1.02
Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation. J Opioid Manag (2014) 0.97
A review of abuse-deterrent opioids for chronic nonmalignant pain. P T (2012) 0.85
Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER). J Clin Pharmacol (2016) 0.84
In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres. J Opioid Manag (2016) 0.84
A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. Pain Med (2015) 0.82
An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia. Curr Med Res Opin (2016) 0.82
Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag (2016) 0.80
Oxycodone DETERx(®): A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain. Pain Ther (2016) 0.80
Oxycodone DETERx(®) ER Capsules: A Review in Severe, Chronic Pain. Drugs (2016) 0.80
Author Correction to: In Vitro Drug Release After Crushing: Evaluation of Xtampza(®) ER and Other ER Opioid Formulations. Clin Drug Investig (2017) 0.75